CRDF Q1 2019 Earnings — Cardiff Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CRDFCardiff Oncology, Inc.

$133M

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$162,000+61.8% YoY

Gross Profit

-$2M-1534.9% margin

Operating Income

-$4M-2445.7% margin

Net Income

-$4M-2410.5% margin

EPS (Diluted)

$-0.96

QoQ Revenue Growth

+107.7%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$200,000

Balance Sheet

Total Assets

$15M

Total Liabilities

$5M

Stockholders' Equity

$10M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$162,000	$100,136	+61.8%
Gross Profit	-$2M	-$266,208	-834.1%
Operating Income	-$4M	-$5M	+14.9%
Net Income	-$4M	-$5M	+18.4%